Vanda Pharmaceuticals Inc (NAS:VNDA)
$ 4.79 -0.06 (-1.24%) Market Cap: 279.21 Mil Enterprise Value: -96.54 Mil PE Ratio: 0 PB Ratio: 0.51 GF Score: 79/100

Q2 2022 Vanda Pharmaceuticals Inc Earnings Call Transcript

Aug 03, 2022 / 08:30PM GMT
Release Date Price: $10.8 (+3.55%)
Operator

Thank you for standing by, and welcome to the Q2 2022 Vanda Pharmaceuticals Inc. Earnings Call. (Operator Instructions)

I'd now like to turn the conference over to Kevin Moran, Vanda's Senior Vice President, Chief Financial Officer and Treasurer. Mr. Moran, please go ahead.

Kevin Patrick Moran
Vanda Pharmaceuticals Inc. - Senior VP, CFO & Treasurer

Thank you very much, Jack. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals' Second Quarter 2022 performance. Our second quarter 2022 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website.

Joining me on today's call is Dr. Mihales Polymeropoulos, our President, Chief Executive Officer and Chairman of the Board. Additionally, we have Tim Williams, our General Counsel; and Gunther Birznieks, our Senior Vice President of Business

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot